Anti-Tumor Activities & CBD

A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

Posted by Joe Pavlik on

Published: British Journal of Cancer (2006) 95, 197–203. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme M Guzmán, M J Duarte, C Blázquez, J Ravina, M C Rosa, I Galve-Roperh, C Sánchez, G Velasco and L González-Feria Abstract Δ9-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we report the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with...

Read more →

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.

Posted by Joe Pavlik on

Published: Oncotarget. 2016 Oct 18. doi: 10.18632/oncotarget.12721. [Epub ahead of print] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Nabissi M, Morelli MB, Offidani M, Amantini C, Gentili S, Soriani A, Cardinali C, Leoni P, Santoni G. Abstract Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma (MM), both alone and in synergy with the proteasome inhibitor bortezomib, to induce cell death. In other type of human cancers, the combination of CBD with Δ9-tetrahydrocannabinol (THC) was...

Read more →

Cannabinoids for Symptom Management and Cancer Therapy: The Evidence.

Posted by Joe Pavlik on

Published: J Natl Compr Canc Netw. 2016 Jul;14(7):915-22. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Davis MP Abstract Cannabinoids bind not only to classical receptors (CB1 and CB2) but also to certain orphan receptors (GPR55 and GPR119), ion channels (transient receptor potential vanilloid), and peroxisome proliferator-activated receptors. Cannabinoids are known to modulate a multitude of monoamine receptors. Structurally, there are 3 groups of cannabinoids. Multiple studies, most of which are of moderate to low quality, demonstrate that tetrahydrocannabinol (THC) and oromucosal cannabinoid combinations of THC and cannabidiol (CBD) modestly reduce cancer pain. Dronabinol and nabilone are better antiemetics...

Read more →